Ligita Jancoriene was graduated from Vilnius University Medical Faculty in 1989 and completed her Residency in Gastroenterology (1993). During her PhD studies she received Clinical Training in Infectious Diseases at Karolinska Institutet, Huddinge University Hospital, Sweden (1999-2003) and defended PhD thesis in a field of Infectious Diseases and Hepatology on the Management of Chronic Viral Hepatitis C (2003). She is working at the Department of Infectious diseases of Vilnius University since 1997 and also working as a Specialist of Infectious diseases and Gastroenterology at the Centre of Infectious diseases in the Vilnius University Hospital Santarisiu Klinikos since 1996. Currently, she is a Professor at the Department of Infectious, Chest diseases, Dermatovenerology and Allergology of Vilnius University and Head of the Department for Consultation and Immunoprophylaxis at the Centre of Infectious diseases in the Vilnius University Hospital Santariškių Klinikos. She is a Member of the European Association of the Study of the Liver and International Society of Travel Medicine. She is a Board Member of the Lithuanian Society of Infectious Diseases and Baltic Immunoprophylaxis Association. She is a co-author of scientific papers in peer-reviewed journals on vaccination and treatment of chronic viral hepatitis C. She was a Principal Investigator in more than 20 clinical trials on viral hepatitis and influenza treatment and vaccination.


The aim of multicenter, international, real-life study was to evaluate efficacy and safety of Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin in treatment-naive and treatment-experienced GT1-infected patients, who failed previous PEG-INF/RBV±first generation protease inhibitor therapy. 114 (54 males) GT1-infected (102-GT1b) patients, aged 54.4±10.6 years, were included. 28.1% were treatment-naive, 71.9% treatment-experienced. 21 patients failed previous triple therapy with telaprevir or boceprevir. 57% were cirrhotics. Treatment was scheduled for 12 weeks in 112, 24 weeks in 2 patients. RBV was administered to 89 patients. Sustained virologic response (SVR12) was assessed by HCV-RNA undetectability 12 weeks after the end of treatment (EOT). 111 patients completed therapy and had undetectable HCV-RNA at the EOT. 73 patients with available follow-up evaluation achieved SVR12. The average reduction in alpha-fetoprotein (16.3 versus 4.9, p<0.001) and hepatic fibrosis (17.3 versus 15.5, p<0.001) was demonstrated at the end of follow-up. RBV was reduced in 18, discontinued in 11 patients. The most frequent adverse events were asthenia (25.4%), fatigue (15.8%), itching (13.2%) and dyspepsia (11.4%). Treatment was disontinued in 3 patients due to exacerbation of psoriasis (day 3), depression (week 5) and elevation of ALT, AST (week 9). 10 liver transplant patients recieved 24 weeks treatment(4 males, 50.7±8.0 years, 9-GT1b, 8-treatment-experienced). RBV was administred to 9, reduced in 3, discontinued in 2 patients. All patients completed therapy and had undetectable HCV-RNR at the EOT. 9 patients with available follow-up evaluation achieved SVR12. In conclusion, treatment with Ombitasvir/Paritaprevir/Ritonavir+Dasabuvir±Ribavirin achieved 100% SVR12. Adverse events were mostly mild and related to RBV administration.

Speaker Presentations

Speaker PPTs

Download PPT